ANDA 80420, held by Abraxis Pharm. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 80420 (Lidocaine Hydrochloride), held by Abraxis Pharm, was first approved by FDA on Feb 15, 1972, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 15, 1972 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride1.5% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters